Viibryd FDA Approval History
FDA Approved: Yes (First approved January 21, 2011)
Brand name: Viibryd
Generic name: vilazodone
Dosage form: Tablets
Company: Allergan plc
Treatment for: Depression
Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).
Development timeline for Viibryd
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.